J. Michael Ryan

4.2k total citations · 1 hit paper
30 papers, 2.1k citations indexed

About

J. Michael Ryan is a scholar working on Physiology, Psychiatry and Mental health and Economics and Econometrics. According to data from OpenAlex, J. Michael Ryan has authored 30 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Physiology, 13 papers in Psychiatry and Mental health and 7 papers in Economics and Econometrics. Recurrent topics in J. Michael Ryan's work include Alzheimer's disease research and treatments (16 papers), Dementia and Cognitive Impairment Research (12 papers) and Health Systems, Economic Evaluations, Quality of Life (7 papers). J. Michael Ryan is often cited by papers focused on Alzheimer's disease research and treatments (16 papers), Dementia and Cognitive Impairment Research (12 papers) and Health Systems, Economic Evaluations, Quality of Life (7 papers). J. Michael Ryan collaborates with scholars based in United States, Switzerland and Canada. J. Michael Ryan's co-authors include Pierre N. Tariot, Karen Dagerman, Sonia M. Davis, David L. Sultzer, Lon S. Schneider, M. Saleem Ismail, Daniel Weintraub, Barry D. Lebowitz, Constantine G. Lyketsos and T. Scott Stroup and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and American Journal of Psychiatry.

In The Last Decade

J. Michael Ryan

30 papers receiving 2.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Effectiveness of Atypical Antipsychotic Drugs in Patients with Alzheimer's Disease

2006 760 citations Lon S. Schneider, Pierre N. Tariot et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
J. Michael Ryan United States	21	971	737	350	295	250	30	2.1k
Jean Georges United Kingdom	22	1.1k 1.2×	514 0.7×	207 0.6×	169 0.6×	580 2.3×	52	2.3k
C. Beck United States	8	1.0k 1.1×	577 0.8×	219 0.6×	128 0.4×	258 1.0×	10	1.6k
Javier Olazarán Spain	28	1.1k 1.1×	456 0.6×	94 0.3×	167 0.6×	216 0.9×	108	2.1k
Gemma‐Claire Ali United Kingdom	8	704 0.7×	366 0.5×	115 0.3×	210 0.7×	339 1.4×	14	1.8k
Ric M. Procyshyn Canada	33	1.6k 1.7×	557 0.8×	392 1.1×	396 1.3×	288 1.2×	143	3.2k
Marta S. Mendiondo United States	22	959 1.0×	689 0.9×	125 0.4×	82 0.3×	146 0.6×	35	2.0k
Raúl L. Arizaga Argentina	12	972 1.0×	391 0.5×	102 0.3×	159 0.5×	337 1.3×	29	1.9k
J. M. Orgogozo France	22	988 1.0×	1.4k 1.9×	385 1.1×	103 0.3×	197 0.8×	40	3.6k
Robert C. Green United States	24	909 0.9×	727 1.0×	129 0.4×	89 0.3×	163 0.7×	31	2.3k
Latha Velayudhan United Kingdom	25	551 0.6×	635 0.9×	178 0.5×	123 0.4×	137 0.5×	69	1.9k

Countries citing papers authored by J. Michael Ryan

Since Specialization

Citations

This map shows the geographic impact of J. Michael Ryan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J. Michael Ryan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J. Michael Ryan more than expected).

Fields of papers citing papers by J. Michael Ryan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J. Michael Ryan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J. Michael Ryan. The network helps show where J. Michael Ryan may publish in the future.

Co-authorship network of co-authors of J. Michael Ryan

This figure shows the co-authorship network connecting the top 25 collaborators of J. Michael Ryan. A scholar is included among the top collaborators of J. Michael Ryan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J. Michael Ryan. J. Michael Ryan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Caputo, Angelika, Amy Racine, Pierre N. Tariot, et al.. (2023). Rationale for the selection of dual primary endpoints in prevention studies of cognitively unimpaired individuals at genetic risk for developing symptoms of Alzheimer’s disease. Alzheimer s Research & Therapy. 15(1). 45–45. 3 indexed citations

Rentz, Dorene M., Alette M. Wessels, Ananth Annapragada, et al.. (2021). Building clinically relevant outcomes across the Alzheimer's disease spectrum. Alzheimer s & Dementia Translational Research & Clinical Interventions. 7(1). e12181–e12181. 28 indexed citations

Coomans, Emma M., Deborah N. Schoonhoven, Hayel Tuncel, et al.. (2021). In vivo tau pathology is associated with synaptic loss and altered synaptic function. Alzheimer s Research & Therapy. 13(1). 35–35. 67 indexed citations

Tuncel, Hayel, Ronald Boellaard, Emma M. Coomans, et al.. (2020). Kinetics and 28-day test–retest repeatability and reproducibility of [¹¹C]UCB-J PET brain imaging. Journal of Cerebral Blood Flow & Metabolism. 41(6). 1338–1350. 17 indexed citations

Ryan, J. Michael, Anna Quattropani, Izaak den Daas, et al.. (2018). O1‐12‐05: PHASE 1 STUDY IN HEALTHY VOLUNTEERS OF THE O‐GLCNACASE INHIBITOR ASN120290 AS A NOVEL THERAPY FOR PROGRESSIVE SUPRANUCLEAR PALSY AND RELATED TAUOPATHIES. Alzheimer s & Dementia. 14(7S_Part_4). 25 indexed citations

Hüll, Michael, Carl Sadowsky, Heii Arai, et al.. (2017). Long-Term Extensions of Randomized Vaccination Trials of ACC-001 and QS-21 in Mild to Moderate Alzheimer’s Disease. Current Alzheimer Research. 14(7). 696–708. 49 indexed citations

Caputo, Angelika, Amy Racine, Edwin P. Martens, et al.. (2017). [O5–01–02]: RATIONALE FOR SELECTION OF PRIMARY ENDPOINTS IN THE ALZHEIMER PREVENTION INITIATIVE GENERATION STUDY IN COGNITIVELY HEALTHY APOE4 HOMOZYGOTES. Alzheimer s & Dementia. 13(7S_Part_30). 1 indexed citations

Weiden, Peter J., et al.. (2016). A Randomized Trial of Iloperidone for Prevention of Relapse in Schizophrenia: The REPRIEVE Study. CNS Drugs. 30(8). 735–747. 21 indexed citations

Dyck, Christopher H. van, Carl Sadowsky, Kevin Booth, et al.. (2016). VANUTIDE CRIDIFICAR (ACC-001) AND QS-21 ADJUVANT IN INDIVIDUALS WITH EARLY ALZHEIMER’S DISEASE: AMYLOID IMAGING POSITRON EMISSION TOMOGRAPHY AND SAFETY RESULTS FROM A PHASE 2 STUDY. The Journal of Prevention of Alzheimer s Disease. 3(2). 1–10. 27 indexed citations

10.

Pasquier, Florence, Carl Sadowsky, Yahong Peng, et al.. (2016). Two Phase 2 Multiple Ascending–Dose Studies of Vanutide Cridificar (ACC-001) and QS-21 Adjuvant in Mild-to-Moderate Alzheimer’s Disease. Journal of Alzheimer s Disease. 51(4). 1131–1143. 77 indexed citations

11.

Winblad, Bengt, Ana Graf, Marie‐Emmanuelle Riviere, Niels Andreasen, & J. Michael Ryan. (2014). Active immunotherapy options for Alzheimer’s disease. Alzheimer s Research & Therapy. 6(1). 7–7. 68 indexed citations

12.

Graf, Ana, Marie‐Emmanuelle Riviere, Angelika Caputo, et al.. (2014). O4‐11‐04: ACTIVE Aβ IMMUNOTHERAPY CAD106 PHASE II DOSE‐ADJUVANT FINDING STUDY: SAFETY AND CNS BIOMARKERS. Alzheimer s & Dementia. 10(4S_Part_5). 2 indexed citations

13.

Caputo, Angelika, Ana Graf, Marie‐Emmanuelle Riviere, et al.. (2014). P1‐360: ACTIVE AB IMMUNOTHERAPY CAD106 PHASE II DOSE‐ADJUVANT FINDING STUDY: AMYLOID PET. Alzheimer s & Dementia. 10(4S_Part_11). 1 indexed citations

14.

McLaughlin, Trent, Howard Feldman, Howard Fillit, et al.. (2010). Dependence as a unifying construct in defining Alzheimer's disease severity. Alzheimer s & Dementia. 6(6). 482–493. 57 indexed citations

15.

Black, Ronald S., Barry Greenberg, J. Michael Ryan, et al.. (2009). Scales as outcome measures for Alzheimer's disease. Alzheimer s & Dementia. 5(4). 324–339. 32 indexed citations

16.

Schneider, Lon S., Pierre N. Tariot, Karen Dagerman, et al.. (2006). Effectiveness of Atypical Antipsychotic Drugs in Patients with Alzheimer's Disease. New England Journal of Medicine. 355(15). 1525–1538. 760 indexed citations breakdown →

17.

Holsworth, Daniel D., Noel A. Powell, Dennis M. Downing, et al.. (2005). Discovery of novel non-peptidic ketopiperazine-based renin inhibitors. Bioorganic & Medicinal Chemistry. 13(7). 2657–2664. 18 indexed citations

18.

Schneider, Lon S., M. Saleem Ismail, Karen Dagerman, et al.. (2003). Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE): Alzheimer's Disease Trial. Schizophrenia Bulletin. 29(1). 57–72. 45 indexed citations

19.

Tariot, Pierre N., et al.. (2002). Mood stabilizers in Alzheimer’s disease: symptomatic and neuroprotective rationales. Advanced Drug Delivery Reviews. 54(12). 1567–1577. 58 indexed citations

20.

Kim, Scott Y. H., Eric D. Caine, Glenn W. Currier, Adrian Leibovici, & J. Michael Ryan. (2001). Assessing the Competence of Persons With Alzheimer’s Disease in Providing Informed Consent for Participation in Research. American Journal of Psychiatry. 158(5). 712–717. 196 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact